Cargando…
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837152/ https://www.ncbi.nlm.nih.gov/pubmed/33530148 http://dx.doi.org/10.1186/s40959-015-0008-5 |
_version_ | 1783642901599748096 |
---|---|
author | Pasvolsky, Oren Leader, Avi Iakobishvili, Zaza Wasserstrum, Yishay Kornowski, Ran Raanani, Pia |
author_facet | Pasvolsky, Oren Leader, Avi Iakobishvili, Zaza Wasserstrum, Yishay Kornowski, Ran Raanani, Pia |
author_sort | Pasvolsky, Oren |
collection | PubMed |
description | Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious consequence of some of the newer TKIs. In this review, we describe the clinical spectrum of TKI-associated VAE, and examine the unique vascular safety profile of the main TKIs currently used in the treatment of CML: imatinib, nilotinib, dasatinib, bosutinib and ponatinib. The issue of TKI-related platelet dysfunction is discussed as well. We describe the contemporary research findings regarding the possible pathogenesis of the VAE. Finally, the different aspects of TKI-associated VAE management are addressed, including prevention methods, monitoring strategies and treatment options. |
format | Online Article Text |
id | pubmed-7837152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78371522021-01-27 Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia Pasvolsky, Oren Leader, Avi Iakobishvili, Zaza Wasserstrum, Yishay Kornowski, Ran Raanani, Pia Cardiooncology Review Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious consequence of some of the newer TKIs. In this review, we describe the clinical spectrum of TKI-associated VAE, and examine the unique vascular safety profile of the main TKIs currently used in the treatment of CML: imatinib, nilotinib, dasatinib, bosutinib and ponatinib. The issue of TKI-related platelet dysfunction is discussed as well. We describe the contemporary research findings regarding the possible pathogenesis of the VAE. Finally, the different aspects of TKI-associated VAE management are addressed, including prevention methods, monitoring strategies and treatment options. BioMed Central 2015-12-04 /pmc/articles/PMC7837152/ /pubmed/33530148 http://dx.doi.org/10.1186/s40959-015-0008-5 Text en © Pasvolsky et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Pasvolsky, Oren Leader, Avi Iakobishvili, Zaza Wasserstrum, Yishay Kornowski, Ran Raanani, Pia Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
title | Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
title_full | Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
title_fullStr | Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
title_full_unstemmed | Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
title_short | Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
title_sort | tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837152/ https://www.ncbi.nlm.nih.gov/pubmed/33530148 http://dx.doi.org/10.1186/s40959-015-0008-5 |
work_keys_str_mv | AT pasvolskyoren tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia AT leaderavi tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia AT iakobishvilizaza tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia AT wasserstrumyishay tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia AT kornowskiran tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia AT raananipia tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia |